抑制病理性血管生成长期以来与肿瘤领域有关，但是现代血管生成研究的新进展已经影响到眼科、心脏病学和妇科等其他非恶性疾病或慢性病领域的疾病治疗进展。此外，血管生成刺激剂广泛应用于缺血性疾病的治疗，而血管生成抑制剂则被用于限制血管形成，但是以明智的方式来修改或“重新编程”血管作为免疫治疗的加强。我们已经注意到，在血管生成领域周围的文献中，引用总数的增加等迹象表明，以血管生成为靶点本身已被确认为治疗多种疾病的可行方法。© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

While inhibiting pathological angiogenesis has been long associated with the field of oncology, recent advances in angiogenesis research have impacted the progress of disease treatment for additional non-malignant diseases or chronic conditions in the fields of ophthalmology, cardiology, and gynecology. Moreover, stimulators of angiogenesis find application in ischemic diseases, while inhibitors of angiogenesis are being used to limit blood vessel formation, but in judicious ways that modify or "reprogram" the vasculature as a reinforcement for immunotherapy. We have noticed an increasing impact, as evidenced by increases in the total number of citations, in the literature surrounding the angiogenesis field suggesting that targeting angiogenesis per se is well established as a tractable approach for therapy in diverse conditions.© 2022. The Author(s), under exclusive licence to Springer Nature B.V.